Key Takeaways
- Shares of BSX declined 9% to close at $62.93, marking the lowest level since January 2024
- The Watchman FLX device met non-inferiority goals against blood thinners, but demonstrated an elevated ischemic stroke rate of 3.2% compared to 2%
- Raymond James lowered BSX from Strong Buy to Outperform, slashing the price target from $97 down to $88
- The firm pointed to decelerating growth in U.S. electrophysiology and Watchman segments, which represented more than 50% of BSX’s annual growth
- Year-to-date, BSX has tumbled 34%, significantly underperforming the S&P 500’s 7.1% decline
Boston Scientific faced significant headwinds this Monday. Shares plummeted 9% following a double blow: disappointing investor reaction to clinical trial findings and an analyst rating cut from Raymond James.
Boston Scientific Corporation, BSX
Data from the CHAMPION-AF trial examining the Watchman FLX device was unveiled at a medical conference on March 30. At first glance, the findings appeared favorable. The device demonstrated non-inferiority when compared to contemporary blood thinners such as Eliquis and Xarelto. Additionally, Watchman recipients experienced a meaningful decrease in non-procedural bleeding events, successfully achieving the trial’s primary objective.
However, market participants fixated on a specific metric. The ischemic stroke incidence among Watchman device recipients reached 3.2%, contrasting with just 2% among patients taking blood thinners. This differential, despite being modest, triggered significant market anxiety.
It’s important to recognize that this variance lacked statistical significance. Furthermore, it wasn’t designated as a primary study outcome. Investigators intend to track participants over a five-year period to obtain more comprehensive stroke risk data.
Medical Experts Defend Trial Outcomes
Marty Leon, the study’s co-chair, characterized the findings as “a very strong endorsement” for broadening the device’s clinical applications. He articulated the benefit-risk profile plainly: an annualized 0.33% increase in stroke or embolization versus approximately a 2.6% decrease in bleeding complications. Boston Scientific’s chief medical officer, Ken Stein, reinforced this perspective, emphasizing that stroke incidence in both cohorts remained “incredibly low.”
Truist Securities observed that overall sentiment at the conference was encouraging. Leerink Partners indicated that firsthand reactions bolstered their conviction that the trial outcomes would drive increased Watchman procedure adoption moving forward.
Nevertheless, the market remained unconvinced. BSX settled at $62.93, representing its weakest closing price since January 30, 2024.
Concurrently, Raymond James revised BSX from Strong Buy to Outperform and reduced its price objective from $97 to $88. The investment firm highlighted weakening momentum in two of BSX’s most significant growth contributors: U.S. electrophysiology and Watchman, which collectively represented 26% of 2025 revenue and drove over half of the company’s year-over-year expansion.
Raymond James Maintains Positive Outlook Despite Revisions
Raymond James analyst Jayson Bedford clarified that the action didn’t reflect diminished confidence in the company’s fundamentals. The firm continues to regard Boston Scientific as among the highest-quality, fastest-expanding enterprises in large-cap medical technology. The rating adjustment stemmed more from reduced short-term certainty rather than fundamental thesis concerns.
The firm reduced its 2026 and 2027 revenue projections by approximately 0.5% and 1.5% respectively. Updated Watchman growth estimates now stand at 17% and 16% for the next two years, down from previous expectations of 18% and 20%. EP growth forecasts were similarly lowered to 15% and 14%.
Despite these adjustments, Raymond James contended the valuation remains compelling. BSX currently trades at roughly 18 times estimated 2027 earnings, compared to 21 times for comparable companies.
Numerous other research firms — including Bernstein, Evercore ISI, Stifel, Truist, and Jefferies — maintain Buy or Outperform recommendations, with price objectives spanning $88 to $120.
BSX has declined 34% year-to-date. The shares reached a 52-week peak of $110 earlier this year.
